A spatially resolved and lipid-structured model for macrophage populations in early human atherosclerotic lesions
Keith L. Chambers, Mary R. Myerscough, Michael G. Watson, Helen M., Byrne

TL;DR
This study develops a spatially-resolved, lipid-structured model for early atherosclerosis, revealing how lipid accumulation and macrophage behavior influence lesion composition and progression.
Contribution
The paper introduces a novel spatially-resolved, lipid-structured model for early atherosclerosis, guided by human lesion images, highlighting macrophage lipid content's role in lesion development.
Findings
Lipid initially accumulates deep in the intima due to LDL retention.
Macrophage mobility sensitivity to lipid content affects lesion morphology.
Lipid content increases with depth regardless of blood LDL/HDL levels.
Abstract
Atherosclerosis is a chronic inflammatory disease of the artery wall. The early stages of atherosclerosis are driven by interactions between lipids and monocyte-derived-macrophages (MDMs). The mechanisms that govern the spatial distribution of lipids and MDMs in the lesion remain poorly understood. In this paper, we develop a spatially-resolved and lipid-structured model for early atherosclerosis. The model development and analysis are guided by images of human coronary lesions by Nakashima et al. 2007. Consistent with their findings, the model predicts that lipid initially accumulates deep in the intima due to a spatially non-uniform LDL retention capacity. The model also qualitatively reproduces the global internal maxima in the Nakashima images only when the MDM mobility is sufficiently sensitive to lipid content, and MDM lifespan sufficiently insensitive. Introducing lipid…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsImmune cells in cancer · Adipokines, Inflammation, and Metabolic Diseases · Atherosclerosis and Cardiovascular Diseases
